Allied Market Research


Lactate Dehydrogenase Kit Market

Lactate Dehydrogenase Kit Market Size, Share, Competitive Landscape and Trend Analysis Report by Sample Type (Serum, Plasma, Cells, Culture, Fermentation Media), by Application (Heart Attack, Anemia, Kidney Disease, Liver disease (Hepatitis and Cirrhosis), Pulmonary Embolism) by End User (Hospitals, Clinics & Pathology Labs, Others) : Global Opportunity Analysis and Industry Forecast, 2022-2032

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

A common medical tool for measuring the amount of lactate dehydrogenase (LDH) in blood serum or even other bodily fluids is indeed the LDH kit. All bodily samples contained the enzyme LDH, which is vital in the process of transforming sugar into energy. An important diagnostic clue regarding tissue injury or diseases like cancer, liver problems, as well as heart attacks could be found in the blood's level of LDH. This kit is indeed a crucial instrument for the evaluation as well as monitoring of numerous health conditions as it is simple to use and yields prompt as well as precise results.
The rising number of chronic illnesses is yet another reason for the increased need for LDH kits, in addition to a demand for easy and rapid diagnosis. LDH levels are commonly used to record the development of diseases like cancer, liver problems, as well as heart disease.
The market is expanding as just a consequence of technological developments inside the formation of LDH kits. For instance, the formation of top rating kits has made it possible to identify extremely low levels of a enzyme, which really is useful for the early identification of some diseases. The advancement of this market is additionally being aided by initiatives as well as financial support for healthcare infrastructure. This same demand for LDH kit is expected to rise in the coming years even though governments as well as healthcare organizations invest inside the development of novel diagnostic tests as well as expanding the availability of healthcare.
The market for LDH kits has enlarged substantially because of technological advances. Developments in analysis of medical images have enabled the development of LDH kits which are more accurate and sensitive. For instance, the adding of monoclonal antibodies has enhanced the accuracy and specificity of LDH kits, allowing the detection of the smallest variations throughout LDH levels.
Improvements were additionally made inside the layout as well as manufacturing of LDH kits. The formation of transportable as well as user-friendly LDH kits that can be used in remote or resource-constrained settings has indeed been facilitated by the use of microfluidics as well as lab-on-a-chip technologies. In addition, such innovations have decreased the duration and costs associated with testing, making it much more available to both patients and healthcare providers. The development of LDH kits that may be connected to smartphones or even other gadgets to enable real-time gathering and analyzing of data is yet another result of the assimilation of electronic and digital technologies. New possibilities as well as applications for point-of-care testing as well as monitoring patients remotely have come about as a consequence of this.
More people seem to be ready to give themselves to routine health screenings as well as tests to identify illnesses initial thanks to an increased focus on preventative care. For the fast and accurate early monitoring and detection of many illnesses, such as melanoma, heart disease, as well as liver disease, LDH kits are indeed an invaluable diagnostic tool. As people are becoming more assertive with their healthcare as well as seek to identify and handle illnesses before they become serious, the demand for LDH kits is therefore likely to rise.
New product launches to flourish in the market
In September 2021, Roche launched a new LDH assay for use on their Cobas c 501/502 and Cobas e 801/e 602 analyzers. The assay is designed for the in vitro quantitative determination of LDH in human serum or plasma and is intended to aid in the diagnosis and monitoring of diseases. In July 2021, BioMedomics launched a new LDH test kit for the detection of LDH in human serum. The kit is designed to provide rapid and accurate results in just 10 minutes and is intended for use in diagnosing and monitoring diseases such as cancer, liver disease, and heart attack. In January 2021, Abbott launched a new LDH test for use on their Architect analyzers. The test is designed to aid in the diagnosis and monitoring of a wide range of diseases and conditions, including liver disease, anemia, and cancer.
Segment Overview: 
By sample type: The LDH kit market is divided into serum, plasma, cells, culture, and fermentation media. LDH kits are used to measure the levels of LDH in these samples, which can indicate tissue damage or disease. Serum and plasma are commonly used samples for LDH testing in clinical settings, while cells, culture, and fermentation media are used for research and industrial purposes. The market is expected to be driven by the increasing demand for LDH kits across these different sample types for both diagnostic and research applications.
By applications: The LDH kit market is divided into heart attack, anemia, kidney disease, liver disease (hepatitis and cirrhosis), and pulmonary embolism. LDH levels in the blood can indicate tissue damage or disease, and abnormalities in LDH levels are associated with various health conditions. For instance, high LDH levels are often observed in individuals with liver disease, while low LDH levels are linked to anemia. The segmentation of this market by application helps to understand the specific disease or condition for which the kit is used, and thus helps to target the relevant patient group. This segmentation can also aid healthcare professionals in making accurate diagnoses and implementing appropriate treatment plans based on the LDH levels observed in patients.
By end user: The LDH kit market is divided into hospitals, clinics & pathology labs, and others. Hospitals and clinics & pathology labs are the major end users of LDH kits. The increasing prevalence of chronic diseases and growing demand for point-of-care testing are driving the growth of this market in hospitals and clinics & pathology labs. The others segment includes academic and research institutes, biotechnology companies, and pharmaceutical companies. These organizations use LDH kits for various R&D purposes. The growing demand for new and innovative LDH kits for research applications is expected to drive growth in the others segment of this market.
By region: The Asia-Pacific (APAC) LDH kit market is expected to experience significant growth in the coming years. Due to the increasing prevalence of various diseases and the growing demand for point-of-care testing in the region, the APACLDH kit market is expected to experience significant growth in the coming years. The rising adoption of advanced technologies in healthcare and the increasing focus on preventive healthcare are also contributing factors. In addition, the presence of key market players and increasing investments in R&D activities are further expected to drive market growth in the region.
Competitive analysis and profiles of the major players in the LDH kit market, such as Abcam Plc, Abnova Co., Bioassay Systems, BioVision, Elabscience Biotechnology Inc., Cell Biologics, Inc., Sigma Aldrich Co. (U.S.), Shanghai Korain Biotech Co. Ltd., Thermo Fisher Scientific Inc., and Weldon Biotech, Inc. Major players have adopted product launch and acquisition as key developmental strategies to improve the product portfolio of this market.

Lactate Dehydrogenase Kit Market Report Highlights

Aspects Details
Lactate Dehydrogenase Kit Market By Sample Type
By Sample Type
  • Serum
  • Plasma
  • Cells
  • Culture
  • Fermentation Media
Lactate Dehydrogenase Kit Market By Application
By Application
  • Heart Attack
  • Anemia
  • Kidney Disease
  • Liver disease (Hepatitis and Cirrhosis)
  • Pulmonary Embolism
Lactate Dehydrogenase Kit Market By End User
By End User
  • Hospitals
  • Clinics & Pathology Labs
  • Others
Lactate Dehydrogenase Kit Market By Region
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players
Key Market Players

Cell Biologics, Inc., Thermo Fisher Scientific Inc., Weldon Biotech, Inc., Shanghai Korain Biotech Co., Ltd., Bioassay Systems, Elabscience Biotechnology Inc., BioVision, Sigma Aldrich Corporation (U.S.), Abcam Plc, Abnova Corporation

Key Market Players

EMELCA Bioscience

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Lactate Dehydrogenase Kit Market

Global Opportunity Analysis and Industry Forecast, 2022-2032